Cingulate Inc. Overview
Pro stress-test →Cingulate Inc. is a biopharmaceutical company focused on the development, manufacturing, and commercialization of pharmaceutical products that utilize its precision timed release (PTR) drug delivery platform technology. The company focuses on the treatment of attention deficit/hyperactivity disorder (ADHD), with a pivotal FDA approval milestone expected in May 2026.
Strategic Profile
Pro stress-test →The company reported positive Phase 3 results for CTx-1301 (dexmethylphenidate HCl) in pediatric ADHD, meeting its primary endpoint and showing dose-dependent improvements with rapid onset and sustained symptom relief up to 12 hours post-dose. Cingulate is preparing commercial infrastructure with partner Indegene, pending FDA approval, positioning itself for a competitive entry into the ADHD treatment market.
Competitive Landscape
Pro stress-test →Cingulate competes in the ADHD treatment market against established players like Neuropathix (Adhansia XR), Shire/Takeda (Adzenys XR-ODT), and others. Its competitive advantage lies in the proprietary PTR platform enabling improved dosing schedules and full active-day coverage. The market opportunity is substantial given ADHD prevalence and patient dissatisfaction with existing regimens.
Industry Context
Cingulate Inc. operates in Biopharmaceuticals - ADHD Treatment.
Key facts
Founded: 2012 · Headquarters: Kansas City, Kansas